Angeliq, a combination oral contraceptive containing drospirenone and ethinyl estradiol, has been discontinued [1]. The reasons for its discontinuation by Bayer are not publicly detailed but often relate to commercial decisions, manufacturing issues, or strategic shifts [1].
When did Angeliq become unavailable?
Angeliq was discontinued in 2019 [2].
What are the alternatives to Angeliq?
For individuals seeking alternatives to Angeliq, other oral contraceptives containing drospirenone are available. Brands that also contain drospirenone and ethinyl estradiol include Yasmin and Yaz [3]. Generic versions of these medications are also on the market [3]. When choosing an alternative, it is advisable to consult with a healthcare provider to determine the most suitable option based on individual health needs and medical history.
Why might a company discontinue a drug like Angeliq?
Drug discontinuations can occur for several reasons. Bayer, like other pharmaceutical companies, may cease production due to insufficient market demand, the introduction of newer or more effective treatments, manufacturing challenges, or regulatory concerns [1]. Commercial viability often plays a significant role in these decisions.
Where can I find information on drug patents and exclusivity?
Information regarding drug patents and exclusivity periods for pharmaceuticals, including contraceptives, can be found on resources like DrugPatentWatch.com [4]. This site provides data on patent status, expiration dates, and other intellectual property details relevant to drug development and market entry.